Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
46-60 of 4127 results
Regulus to discontinue clinical development of HCV candidate RG-101
By PBR Staff Writer
Regulus Therapeutics said it intends to discontinue clinical development of RG-101, a microRNA treatment for hepatitis C.
Contract Research & Services > Clinical Trials > News
Probiodrug unveils encouraging results of phase 2a SAPHIR study in AD patients
Probiodrug has reported positive results for its PQ912 candidate in a Phase 2a SAPHIR study in early Alzheimer’s disease (AD) patients.
Contract Research & Services > Clinical Trials > News
Merck and Pfizer's ertugliflozin meets primary endpoints in two type 2 diabetes studies
Merck, in partnership with Pfizer, announced that two phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help enhance glycemic control in adults with type 2 diabetes, met their primary endpoints.
Contract Research & Services > Clinical Trials > News
AbbVie's rheumatoid arthritis drug succeeds in phase 3 study
By PBR Staff Writer
AbbVie's Upadacitinib (ABT-494) has met all primary and ranked secondary endpoints in a phase 3 trial in rheumatoid arthritis (RA).
Contract Research & Services > Clinical Trials > News
Teva's migraine candidate fremanezumab succeeds in second phase III study
Teva Pharmaceutical Industries’ Fremanezumab has meets all primary & secondary endpoints across both monthly and quarterly dosing regimens in phase III study in episodic migraine prevention.
Contract Research & Services > Clinical Trials > News
Juno announces updated data from trial of JCAR017 in r/r aggressive B cell NHL
Juno Therapeutics has presented updated TRANSCEND NHL 001 trial data showing high durable response rates in patients with relapsed or refractory CD19+ aggressive non-hodgkin lymphoma at the 2017 Annual Meeting of the American Society for Clinical Oncology (ASCO).
Contract Research & Services > Clinical Trials > News
Roche’s Perjeta-based regimen cuts down breast cancer recurrence in phase 3 trial
By PBR Staff Writer
Roche’s Perjeta-based regimen has succeeded in a phase 3 trial by reducing the risk of recurrence of breast cancer by 19% in people with HER2-positive early breast cancer (eBC).
Contract Research & Services > Clinical Trials > News
J&J’s prostate cancer drug Zytiga shows significant effect in phase 3 trial
By PBR Staff Writer
Johnson & Johnson’s (J&J) prostate cancer drug Zytiga (abiraterone acetate) has showed a significant effect in the phase 3 LATITUDE clinical trial.
Contract Research & Services > Clinical Trials > News
Teva’s phase 3 study of migraine drug fremanezumab yields positive results
Teva Pharmaceutical Industries has reported positive results from a Phase III HALO study for its migraine drug fremanezumab.
Contract Research & Services > Clinical Trials > News
Lilly’s cyramza succeeds in phase 3 urothelial cancer trial
By PBR Staff Writer
Eli Lilly's Cyramza (ramucirumab), in combination with docetaxel, has succeeded in a phase 3 urothelial cancer trial by meeting its primary endpoint of significantly improving progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
Lysogene completes patient enrollment in first observational study in MPS IIIA
Biopharmaceutical firm Lysogene has completed enrollment of patients in its “Sanfilippo A Multi-national Observational Study” (SAMOS).
Contract Research & Services > Clinical Trials > News
New drug candidate shown to delay motor neurone disease onset
By PBR Staff Writer
Scientists at the University of Sheffield in the UK have reported encouraging early results in study of a potential drug to combat a form of motor neurone disease.
Contract Research & Services > Clinical Trials > News
Neurocrine’s Ingrezza fails in phase II Tourette syndrome study
Neurocrine Biosciences said that the initial phase II Tourette syndrome T-Force GREEN study of INGREZZA (valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint.
Contract Research & Services > Clinical Trials > News
Inovio’s HIV vaccine succeeds in early stage trial
Inovio Pharmaceuticals' Pennvax-GP HIV vaccine has demonstrated nearly 100% immune response rates in a clinical study.
Contract Research & Services > Clinical Trials > News
FDA places clinical hold on Concert Pharmaceuticals’ hair loss drug
The US Food and Drug Administration (FDA) has placed a clinical hold on Concert Pharmaceuticals’ CTP-543 Phase 2a clinical trial for alopecia areata.
Contract Research & Services > Clinical Trials > News
46-60 of 4127 results